12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RG3039: Phase Ib started

Repligen began a double-blind, placebo-controlled, U.S. Phase Ib trial evaluating multiple ascending-doses of oral RG3039 for 28 days in 32 healthy adult volunteers. RG3039 has Orphan...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >